DAAs proves capable for HCV-infected heart transplant patients
from MD Magazine
Direct-acting antiviral (DAA) drugs proved safe and effective for hepatitis C (HCV) patients who had undergone heart transplants, according to new research. Jia-Horng Kao, MD, PhD, FAASLD, and a team from the National Taiwan University Hospital in Taipei, found that 12 individuals given sofosbuvir combined with ledipasvir (Harvoni) or sofosbuvir (Sovaldi) combined with daclatasvir (Daklinza) achieved a sustained virologic response rate of 100% after 12 weeks.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063